etherna, a leading mRNA technologies company, today announced the appointment of Antonin (Tony) de Fougerolles as Chair. Tony has served as an Independent Board Member since January 2023. The outgoing Chair, Marijn Dekkers, will remain on the Board.
In addition to his role as Chair, Tony will also take an active consultancy role for the Company. I am absolutely thrilled to be able to work more closely with Tony. His vast experience, connections, and strategic vision in the field will further accelerate the development and success of the Company.
I also want to thank Marijn for the close collaboration over the last eight months, which has been inspirational. Bernard Sagaert, CEO, etherna Tony de Fougerolles, etherna Chair , added: “Over the last 18 months, I have seen first-hand how the cLNPs and mRNA manufacturing expertise that etherna has developed is world-leading and impressive in its quality, breadth, and novelty. The recently announced partnership with Almirall is clear recognition of this.
I am excited to accept the role of Chair and look forward to actively helping Bernard and his talented team take full advantage of the exciting opportunities to help our partners bring novel mRNA-based therapeutics to patients. Marijn Dekkers, etherna Independent Board Member, noted: “Tony has already proven to be an extremely valued addition to the Board, and therefore, I am delighted to welcome him as my successor. His combination of scientific and entrepreneurial excellence as.